HLB (028300) Q2 2024 earnings summary

Executive summary

• Operates in three main segments: healthcare (diagnostics, medical devices), bio (oncology drug development), and shipbuilding (specialty vessels, pipes).

• Recent focus on expanding bio and healthcare, with shipbuilding spun off in May 2023.

• Major R&D investments in oncology drugs (Rivoceranib) and immunotherapy platforms.

Financial highlights

• 2024 H1 consolidated revenue: ₩25.95B, down from ₩42.9B in H1 2023.

• Operating loss: ₩73.24B (H1 2023: ₩125.02B loss).

• Net loss: ₩78.92B (H1 2023: ₩206.04B loss).

• Cash and equivalents at June 2024: ₩69.49B, down from ₩108.89B at end-2023.

• Equity ratio: 71.6%; debt ratio: 39.3% (up from 29.1% at end-2023).

Outlook and guidance

• Focus on FDA approval and commercialization of Rivoceranib for liver cancer.

• Plans to expand product pipeline and global market presence in oncology and diagnostics.

• Continued investment in R&D and strategic acquisitions to drive future growth.